Robert W. Robey
YOU?
Author Swipe
View article: Angulin-1/LSR inhibition transiently disrupts the blood-tumor barrier to enhance doxil permeability and impair malignant glioma progression
Angulin-1/LSR inhibition transiently disrupts the blood-tumor barrier to enhance doxil permeability and impair malignant glioma progression Open
The blood-tumor barrier (BTB) prevents effective central nervous system (CNS) drug delivery, especially in malignant gliomas. Brain endothelium predominates the BTB and connects through bicellular and tricellular tight junctions (TJ). Angu…
View article: Functional Implications of the Conformational Landscape of a Multidrug Transporter Revealed by Structures of Zebrafish Abcb4
Functional Implications of the Conformational Landscape of a Multidrug Transporter Revealed by Structures of Zebrafish Abcb4 Open
The hallmark of multidrug resistance conferred by human ABC transporter ABCB1 (hP-gp) is the recognition and efflux of diverse range of drugs, though the precise mechanism of polyspecificity remains unresolved. In aquatic animals such as z…
View article: Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters
Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters Open
Aim Antibody-drug conjugates (ADCs) feature an antibody recognizing a specific protein joined to a potent toxic payload. Numerous antibody-drug conjugates have received FDA approval; however, clinical resistance arises. Resistance mechanis…
View article: A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter <i>SLC43A1</i> (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter <i>SLC43A1</i> (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells Open
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States, with a five-year survival rate of 65%. Oxaliplatin was the first platinum drug shown to improve CRC patient outcomes and is now a common adjuvant th…
View article: Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Table 2, related to Figure 5 and 6.
View article: Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 1 related to Figure 2
View article: Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 4
View article: Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 2 related to Figure 4
View article: Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Table 1
View article: Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 3 related to Figure 8
View article: Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib Open
Isocitrate dehydrogenase (IDH)-mutant gliomas have distinctive metabolic and biological traits that potentially render them susceptible to targeted treatments. Here, by conducting a high-throughput drug screen, we pinpointed a specific vul…
View article: EXTH-22. TARGETING MITOCHONDRIAL PROTEASE IN DIFFUSE GLIOMAS
EXTH-22. TARGETING MITOCHONDRIAL PROTEASE IN DIFFUSE GLIOMAS Open
BACKGROUND Targeting mitochondrial function has emerged as a promising therapeutic strategy in cancer treatment. TR107 is characterized as a specific activator of caseinolytic protease proteolytic subunit (ClpP) in the mitochondria, potent…
View article: Figure 2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
RNA-seq (xsq) expression of hormonal and drug efflux genes in the ACC cell lines and surgical samples. A, Univariate analysis scatterplot of the hormonal genes SULT2A1 (sulfotransferase family 1A member 1) vs. CYP11A1 (cytochrome P450 fami…
View article: Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 2 related to Figure 4
View article: Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 4
View article: Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Table 1
View article: Figure 1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Overview of the datasets and reproducibility of ACC CellMiner. A, URL and snapshot of the website for ACC_CellMinerCDB. B, Summary of the molecular and drug activity data for cell lines, patient-derived mouse xenografts, and surgical sampl…
View article: Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 3 related to Figure 8
View article: Figure 3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 3 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Comparison of gene expression of CU-ACC cell lines and original PDXs. A, Overall correlation between gene expression in the cancer cell lines evaluated at the NCI and CU and their corresponding PDXs. Areas shaded in gray highlight the grou…
View article: Figure 8 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 8 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
The CU-ACC1 cell line is sensitive to temozolomide as it lacks MGMT and is MMR proficient, whereas CU-ACC2 cells are resistant to temozolomide because of MMR deficiency. A, CU-ACC1 and CU-ACC2 do not express MGMT transcripts. Univariate sc…
View article: Figure 4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 4 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Examples of biomarker signatures in the ACC cell lines and surgical samples. A, The ADS varies across ACC cell lines and surgical samples and is correlated with the expression of LSS (lanosterol synthase), a key enzyme in cholesterol biosy…
View article: Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Table S2 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Table 2, related to Figure 5 and 6.
View article: Figure 5 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 5 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Several ACC cell lines and surgical samples do not express TERT. A, Univariate scatterplot of TERT transcriptional expression levels vs. ATRX transcriptional expression levels in the ACC cell line and surgical sample data set. B, Alternati…
View article: Figure 7 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 7 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
A, Correlation between the activity of mitotane tested at the NCI and the expression of SOAT1. B, Correlation between the activity of mitotane tested independently at the NCAT and the expression of SOAT1. C, Correlation between the express…
View article: Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure S1 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Supplement Figure 1 related to Figure 2
View article: Figure 6 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
Figure 6 from A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples Open
Examples of gene copy number variations and mutations in the ACC cell lines. A, CU-ACC1 is defective in CDKN2A. Univariate scatterplot of CDKN2A transcriptional expression levels vs. CDKN2A gene copy number in the ACC NCI cell line data se…
View article: Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma
Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma Open
Immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy. However, given the limited number of current targets, the identification of new surface proteins, particularly those with biological importan…
View article: Self‐Assembled Verteporfin Nanoparticles for Photodynamic and Light‐Independent Therapy in Glioblastoma
Self‐Assembled Verteporfin Nanoparticles for Photodynamic and Light‐Independent Therapy in Glioblastoma Open
Verteporfin (VP) has been used for photodynamic therapy (PDT) for over 20 years, and new applications have brought it back into the spotlight. VP is hydrophobic and requires lipid carriers for clinical delivery as Visudyne. A nanosuspensio…